Abstract
A number of studies over the last two decades have demonstrated the critical importance of dopamine (DA) in the behavioral pharmacology and addictive properties of abused drugs. The DA transporter (DAT) is a major target for drugs of abuse in the category of psychostimulants, and for methylphenidate (MPH), a drug used for treating attention deficit hyperactivity disorder (ADHD), which can also be a psychostimulant drug of abuse. Other drugs of abuse such as nicotine, ethanol, heroin and morphine interact with the DAT in more indirect ways. Despite the different ways in which drugs of abuse can affect DAT function, one evolving theme in all cases is regulation of the DAT at the level of surface expression. DAT function is dynamically regulated by multiple intracellular and extracellular signaling pathways and several protein-protein interactions. In addition, DAT expression is regulated through the removal (internalization) and recycling of the protein from the cell surface. Furthermore, recent studies have demonstrated that individual differences in response to novel environments and psychostimulants can be predicted based on individual basal functional DAT expression. Although current knowledge of multiple factors regulating DAT activity has greatly expanded, many aspects of this regulation remain to be elucidated; these data will enable efforts to identify drugs that might be used therapeutically for drug dependence therapeutics.
Keywords: Dopamine, dopamine transporter, trafficking, nicotine, amphetamine, cocaine, ethanol, opioid, individual differences, environmental enrichment, addiction
CNS & Neurological Disorders - Drug Targets
Title: Role of the Dopamine Transporter in the Action of Psychostimulants, Nicotine, and Other Drugs of Abuse
Volume: 7 Issue: 5
Author(s): J. Zhu and M. E.A. Reith
Affiliation:
Keywords: Dopamine, dopamine transporter, trafficking, nicotine, amphetamine, cocaine, ethanol, opioid, individual differences, environmental enrichment, addiction
Abstract: A number of studies over the last two decades have demonstrated the critical importance of dopamine (DA) in the behavioral pharmacology and addictive properties of abused drugs. The DA transporter (DAT) is a major target for drugs of abuse in the category of psychostimulants, and for methylphenidate (MPH), a drug used for treating attention deficit hyperactivity disorder (ADHD), which can also be a psychostimulant drug of abuse. Other drugs of abuse such as nicotine, ethanol, heroin and morphine interact with the DAT in more indirect ways. Despite the different ways in which drugs of abuse can affect DAT function, one evolving theme in all cases is regulation of the DAT at the level of surface expression. DAT function is dynamically regulated by multiple intracellular and extracellular signaling pathways and several protein-protein interactions. In addition, DAT expression is regulated through the removal (internalization) and recycling of the protein from the cell surface. Furthermore, recent studies have demonstrated that individual differences in response to novel environments and psychostimulants can be predicted based on individual basal functional DAT expression. Although current knowledge of multiple factors regulating DAT activity has greatly expanded, many aspects of this regulation remain to be elucidated; these data will enable efforts to identify drugs that might be used therapeutically for drug dependence therapeutics.
Export Options
About this article
Cite this article as:
Zhu J. and Reith E.A. M., Role of the Dopamine Transporter in the Action of Psychostimulants, Nicotine, and Other Drugs of Abuse, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927877
DOI https://dx.doi.org/10.2174/187152708786927877 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Biology of Jatropha curcas: A Mini Review
Current Pharmaceutical Biotechnology Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Processed Gingers: Current and Prospective Use in Food, Cosmetic, and Pharmaceutical Industry
Recent Patents on Food, Nutrition & Agriculture Preparation, Characterization, and In Vitro Release of Vinorelbine Tartrate (VLBT)- Loaded Folate-conjugated Recombination Human Serum Albumin (rHSA) Nanoparticles with Different Degree of Cross-linking
Current Nanoscience Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer’s Disease and Other Inflammation-related Pathologies
Current Alzheimer Research Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Educational Strategies of Diabetes Group Medical Visits: A Review
Current Diabetes Reviews Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Therapies for Neurological Disease in the Mucopolysaccharidoses
Current Gene Therapy Meet Our Editorial Board Member
Letters in Drug Design & Discovery The mAP-KL Algorithm Combined with Mutual Information Network Used to Screen Hub Genes in Osteosarcoma
Current Bioinformatics Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design NBS1 Heterozygosity and Cancer Risk
Current Genomics Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design CAM Use in Pediatric Oncology
Current Pediatric Reviews Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry